[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1976

A Controlled Trial of Amantadine in Drug-Induced Extrapyramidal Disorders

Author Affiliations

From the Department of Mental Health, Commonwealth of Massachusetts (Dr DiMascio and Mr Marder), Tufts University School of Medicine (Dr DiMascio), Boston, Foxborough (Mass) State Hospital (Dr Bernardo), Massachusetts General Hospital, and Harvard Medical School, Boston (Dr Greenblatt).

Arch Gen Psychiatry. 1976;33(5):599-602. doi:10.1001/archpsyc.1976.01770050055008
Abstract

• Presently marketed antiparkinsonism drugs are potent anticholinergic agents that, while effective in treating extrapyramidal symptoms (EPS), also are productive of or can exacerbate a number of side effects associated with psychotropic drugs. Some of these include gastrointestinal disturbances, visual difficulties, and tardive dyskinesia.

A double-blind study was carried out to assess the efficacy (and adverse effects) of amantadine hydrochloride—an agent without appreciable anticholinergic activity—for the treatment of drug-induced EPS.

Amantadine was found to be comparable in effect to benztropine mesylate, but with fewer side effects. The potential role of amantadine may be in the treatment of patients with druginduced EPS for whom medication with anticholinergic properties is contraindicated.

×